Abstract
Background
Sequential and concomitant therapies are two innovative therapies for Helicobacter pylori (H. pylori) eradication. However, the comparative efficacy and safety of these treatments are controversial. Therefore, we aimed to conduct an updated systematic review and meta-analysis of studies that compared these two treatments.
Methods
A search of PubMed, Embase, the Cochrane Library, and Web of Science was carried out. Randomized controlled trials (RCTs) that compared sequential with concomitant therapies were selected for meta-analysis.
Results
Twenty RCTs were included in the analysis. The eradication rate of 10-day sequential therapy was superior to that of 5-day concomitant therapy (82.09 versus 77.79%, relative risk (RR) 1.052 (95% confidence interval (CI) 1.004–1.103), P = 0.035)), similar to that of 7-day concomitant therapy (82.40 versus 86.99%, RR 0.959 (95% CI 0.874–1.053), P = 0.382), and inferior to that of 10-day concomitant therapy (78.39 versus 83.32%, RR 0.945 (95% CI 0.907–0.984, P = 0.006); the occurrence of diarrhea was higher in 10-day concomitant therapy than that in 10-day sequential therapy. Compared with the eradication rate of sequential therapy, that of concomitant therapy was higher in metronidazole-resistant strains (RR 0.912 (95% CI 0.844–0.986, P = 0.020)) and strains resistant to metronidazole and clarithromycin (RR 0.542 (95% CI 0.308–0.956, P = 0.035)).
Conclusion
The efficacy of concomitant therapy was duration dependent, and 10-day concomitant therapy was superior to 10-day sequential therapy. Compared to sequential therapy, concomitant therapy was more efficacious for metronidazole-resistant strains and metronidazole plus clarithromycin-resistant strains. However, diarrhea was more frequent with concomitant therapy than with sequential therapy.
Similar content being viewed by others
References
Malfertheiner P, Chan FK, McColl KE (2009) Peptic ulcer disease. Lancet 374:1449–1461. https://doi.org/10.1016/S0140-6736(09)60938-7
Suerbaum S, Michetti P (2002) Helicobacter pylori infection. N Engl J Med 347:1175–1186. https://doi.org/10.1056/NEJMra020542
Gisbert JP, Calvet X (2011) Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori. Aliment Pharm Ther 34:604–617
Tonkic A, Tonkic M, Lehours P, Megraud F (2012) Epidemiology and diagnosis of Helicobacter pylori infection. Helicobacter 17(Suppl 1):1–8. https://doi.org/10.1111/j.1523-5378.2012.00975.x
Rizwan M, Fatima N, Alvi A (2014) Epidemiology and pattern of antibiotic resistance in Helicobacter pylori: Scenario from Saudi Arabia. Saudi J Gastroenterol 20:212–218. https://doi.org/10.4103/1319-3767.136935
Chey WD, Wong BC (2007) American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 102:1808–1825. https://doi.org/10.1111/j.1572-0241.2007.01393.x
Georgopoulos SD, Papastergiou V, Karatapanis S (2013) Current options for the treatment of Helicobacter pylori. Expert Opin Pharmacother 14:211–223. https://doi.org/10.1517/14656566.2013.763926
Graham DY, Fischbach L (2010) Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 59:1143–1153. https://doi.org/10.1136/gut.2009.192757
Iwanczak F, Iwanczak B (2012) Treatment of Helicobacter pylori infection in the aspect of increasing antibiotic resistance. Adv Clin Exp Med 21:671–680
Zullo A, Rinaldi V, Winn S, Meddi P, Lionetti R, Hassan C, Ripani C et al (2000) A new highly effective short-term therapy schedule for Helicobacter pylori eradication. Aliment Pharmacol Ther 14:715–718
Romano M, Cuomo A, Gravina AG, Miranda A, Iovene MR, Tiso A, Sica M et al (2010) Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial. Gut 59:1465–1470. https://doi.org/10.1136/gut.2010.215350
Liou JM, Chen CC, Chen MJ, Chen CC, Chang CY, Fang YJ, Lee JY et al (2013) Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet 381:205–213. https://doi.org/10.1016/S0140-6736(12)61579-7
Yoon H, Lee DH, Kim N, Park YS, Shin CM, Kang KK, Oh DH et al (2013) Meta-analysis: is sequential therapy superior to standard triple therapy for Helicobacter pylori infection in Asian adults? J Gastroenterol Hepatol 28:1801–1809. https://doi.org/10.1111/jgh.12397
O’Connor A, Vaira D, Gisbert JP, O’Morain C (2014) Treatment of Helicobacter pylori Infection 2014. Helicobacter 19(Suppl 1):38–45. https://doi.org/10.1111/hel.12163
Treiber G, Ammon S, Schneider E, Klotz U (1998) Amoxicillin/metronidazole/omeprazole/clarithromycin: a new, short quadruple therapy for Helicobacter pylori eradication. Helicobacter 3:54–58
Okada M, Oki K, Shirotani T, Seo M, Okabe N, Maeda K, Nishimura H et al (1998) A new quadruple therapy for the eradication of Helicobacter pylori. Effect of pretreatment with omeprazole on the cure rate. J Gastroenterol 33:640–645
Heo J, Jeon SW, Jung JT, Kwon JG, Kim EY, Lee DW, Seo HE et al (2014) A randomised clinical trial of 10-day concomitant therapy and standard triple therapy for Helicobacter pylori eradication. Dig Liver Dis 46:980–984. https://doi.org/10.1016/j.dld.2014.07.018
Kanizaj TF, Kunac N (2014) Helicobacter pylori: future perspectives in therapy reflecting three decades of experience. World J Gastroenterol 20:699–705. https://doi.org/10.3748/wjg.v20.i3.699
He L, Deng T, Luo H (2015) Meta-analysis of sequential, concomitant and hybrid therapy for Helicobacter pylori eradication. Intern Med 54:703–710. https://doi.org/10.2169/internalmedicine.54.3442
Kim JS, Park SM, Kim BW (2015) Sequential or concomitant therapy for eradication of Helicobacter pylori infection: a systematic review and meta-analysis. J Gastroenterol Hepatol 30:1338–1345. https://doi.org/10.1111/jgh.12984
Gatta L, Vakil N, Vaira D, Scarpignato C (2013) Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ 347:f4587
Malfertheiner P, Megraud F, O’Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F et al (2017) Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report. Gut 66:6–30. https://doi.org/10.1136/gutjnl-2016-312288
Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097. https://doi.org/10.1371/journal.pmed.1000097
Greenberg ER, Anderson GL, Morgan DR, Torres J, Chey WD, Bravo LE, Dominguez RL et al (2011) 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet 378:507–514
Federico A, Nardone G, Gravina AG, Iovene MR, Miranda A, Compare D, Pilloni PA et al (2012) Efficacy of 5-day levofloxacin-containing concomitant therapy in eradication of Helicobacter pylori infection. Gastroenterology 143:55–61
Zullo A, Scaccianoce G, De Francesco V, Ruggiero V, D’Ambrosio P, Castorani L, Bonfrate L et al (2013) Concomitant, sequential, and hybrid therapy for H. pylori eradication: a pilot study. Clin Res Hepatol Gas 37:647–650
De Francesco V, Hassan C, Ridola L, Giorgio F, Ierardi E, Zullo A (2014) Sequential, concomitant and hybrid first-line therapies for Helicobacter pylori eradication: a prospective randomized study. J Med Microbiol 63:748–752
Hsu PI, Wu DC, Chen WC, Tseng HH, Yu HC, Wang HM, Kao SS et al (2014) Randomized controlled trial comparing 7-day triple, 10-day sequential, and 7-day concomitant therapies for Helicobacter pylori infection. Antimicrob Agents Chemother 58:5936–5942. https://doi.org/10.1128/aac.02922-14
Lee HJ, Kim JI, Lee JS, Jun EJ, Oh JH, Cheung DY, Chung WC et al (2015) Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies. World J Gastroenterol 21:351–359. https://doi.org/10.3748/wjg.v21.i1.351
Tepes B, Vujasinovic M, Seruga M, Stefanovic M, Forte A, Jeverica S (2016) Randomized clinical trial comparing 10-day sequential, 7-day concomitant and 7-day standard triple therapies for Helicobacter pylori eradication. Eur J Gastroenterol Hepatol 28:676–683. https://doi.org/10.1097/MEG.0000000000000590
Wu D, Hsu P, Wu J, Opekun AR, Kuo C, Wu I, Wang SSW et al (2010) Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection. Clin Gastroenterol H 8:36–41
Huang YK, Wu MC, Wang SS, Kuo CH, Lee YC, Chang LL, Wang TH et al (2012) Lansoprazole-based sequential and concomitant therapy for the first-line Helicobacter pylori eradication. J Dig Dis 13:232–238. https://doi.org/10.1111/j.1751-2980.2012.00575.x
McNicholl AG, Marin AC, Molina-Infante J, Castro M, Barrio J, Ducons J, Calvet X et al (2014) Randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice. Gut 63:244–249
Ang TL, Fock KM, Song M, Ang D, Kwek AB, Ong J, Tan J et al (2015) Ten-day triple therapy versus sequential therapy versus concomitant therapy as first line treatment for Helicobacter pylori infection. J Gastroenterol Hepatol 30:1134–1139. https://doi.org/10.1111/jgh.12892
Gungor G, Baglicakoglu M, Kayacetin E, Biyik M, Ucar R, Goktepe H, Ataseven H et al (2015) Current status of five different regimens for empiric first-line Helicobacter pylori eradication in Turkey. Digestion 92:55–59. https://doi.org/10.1159/000434627
Apostolopoulos P, Koumoutsos I, Ekmektzoglou K, Dogantzis P, Vlachou E, Kalantzis C, Tsibouris P et al (2016) Concomitant versus sequential therapy for the treatment of Helicobacter pylori infection: a Greek randomized prospective study. Scand J Gastroenterol 51:145–151. https://doi.org/10.3109/00365521.2015.1079646
Basyigit S, Sapmaz F, Kefeli A, Yeniova AO, Asilturk Z, Hokkaömeroğlu M, Uzman M et al (2016) Increasing antibiotic resistance is the main cause for the failure of helicobacter pylori eradication: comparison of three trusted treatment protocols. Acta Medica Mediterr 32:297–302. 10.19193/0393-6384_2016_2_44
Chung JW, Han JP, Kim KO, Kim SY, Hong SJ, Kim TH, Kim CW et al (2016) Ten-day empirical sequential or concomitant therapy is more effective than triple therapy for Helicobacter pylori eradication: a multicenter, prospective study. Dig Liver Dis 48:888–892. https://doi.org/10.1016/j.dld.2016.05.005
Das R, Sureshkumar S, Sreenath GS, Kate V (2016) Sequential versus concomitant therapy for eradication of Helicobacter Pylori in patients with perforated duodenal ulcer: a randomized trial. Saudi J Gastroenterol 22:309–315. https://doi.org/10.4103/1319-3767.187605
Georgopoulos SD, Xirouchakis E, Martinez-Gonzales B, Zampeli E, Grivas E, Spiliadi C, Sotiropoulou M et al (2016) Randomized clinical trial comparing ten day concomitant and sequential therapies for Helicobacter pylori eradication in a high clarithromycin resistance area. Eur J Intern Med 32:84–90. https://doi.org/10.1016/j.ejim.2016.04.011
Kefeli A, Basyigit S, Yeniova AO, Kefeli TT, Aslan M, Tanas O (2016) Comparison of three different regimens against Helicobacter pylori as a first-line treatment: a randomized clinical trial. Bosn J Basic Med Sci 16:52–57. 10.17305/bjbms.2016.660
Park SM, Kim JS, Kim BW, Ji JS, Choi H (2016) A randomised clinical trial comparing 10- or 14-day sequential therapy and 10- or 14-day concomitant therapy for the first line empirical treatment of Helicobacter pylori infection. J Gastroenterol Hepatol 32:589–594. https://doi.org/10.1111/jgh.13510
Lim JH, Lee DH, Choi C, Lee ST, Kim N, Jeong SH, Kim JW et al (2013) Clinical outcomes of two-week sequential and concomitant therapies for Helicobacter pylori eradication: a randomized pilot study. Helicobacter 18:180–186
Higgins J, Sally (2008) Chapter 8: assessing risk of bias in included studies. In: Cochrane Handbook for Systematic Reviews of Interventions. ed. John Wiley & Sons, pp187–241
Morgan DR, Torres J, Sexton R, Herrero R, Salazar-Martinez E, Greenberg ER, Bravo LE et al (2013) Risk of recurrent Helicobacter pylori infection 1 year after initial eradication therapy in 7 Latin American communities. JAMA 309:578–586. https://doi.org/10.1001/jama.2013.311
Ang TL, Fock KM, Ang D (2013) A randomized controlled trial of triple therapy versus sequential therapy versus concomitant therapy as first line treatment for H. pylori infection. Gastroenterology 144:S53
Yasser FAS, Haneen Y (2013) Treatment of Helicobacter pylori, comparison of three regimens, a double blind randomized trial. J Gastroenterol Hepatol (Hong Kong) 2:699–702
Jung SM, Cheung DY, Kim JI, Kim I, Seong H (2016) Comparing the efficacy of concomitant therapy with sequential therapy as the first-line therapy of Helicobacter pylori eradication. Gastroenterol Res Pract 2016:1293649. https://doi.org/10.1155/2016/1293649
Kim SY, Park DK, Kwon KA, Kim KO, Kim YJ, Chung J (2014) Ten day concomitant therapy is superior to ten day sequential therapy for Helicobacter pylori eradication. Korean J Gastroenterol 64:260–267
Ang TL, Fock KM, Song M, Ang D, Kwek ABE, Ong J, Tan J et al (2015) Ten-day triple therapy versus sequential therapy versus concomitant therapy as first-line treatment for Helicobacter pylori infection. J Gastroen Hepatol 30:1134–1139. https://doi.org/10.1111/jgh.12892
Malfertheiner P, Megraud F, O’Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF et al (2012) Management of Helicobacter pylori infection—the Maastricht IV/ Florence Consensus Report. Gut 61:646–664. https://doi.org/10.1136/gutjnl-2012-302084
Kuo CH, Kuo FC, Hu HM, Liu CJ, Wang SS, Chen YH, Hsieh MC et al (2012) The optimal first-line therapy of Helicobacter pylori infection in year 2012. Gastroenterol Res Pract 2012:168361. https://doi.org/10.1155/2012/168361
Zullo A, De Francesco V, Hassan C (2010) Sequential or concomitant therapy for Helicobacter pylori eradication? J Clin Gastroenterol 44(658):658–659. https://doi.org/10.1097/MCG.0b013e3181d6b543
Yeo YH, Shiu SI, Ho HJ, Zou B, Lin JT, Wu MS, Liou JM et al (2016) First-line Helicobacter pylori eradication therapies in countries with high and low clarithromycin resistance: a systematic review and network meta-analysis. Gut:1–8. doi: https://doi.org/10.1136/gutjnl-2016-311868
Hersoug LG, Moller P, Loft S (2016) Gut microbiota-derived lipopolysaccharide uptake and trafficking to adipose tissue: implications for inflammation and obesity. Obes Rev 17:297–312. https://doi.org/10.1111/obr.12370
Molina-Infante J, Romano M, Fernandez-Bermejo M, Federico A, Gravina AG, Pozzati L, Garcia-Abadia E et al (2013) Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance. Gastroenterology 145:121–128. https://doi.org/10.1053/j.gastro.2013.03.050
Funding
This work was supported by the National Key Research and Development Program of China (no. 2016YFC1302201), the National Natural Science Foundation of China (81460115), the Science and Technology Projects of Jiangxi province (2014BBG70019), and Special funds of the graduate student innovation project in Jiangxi province in 2014 (no: YC2014-S081).
Author information
Authors and Affiliations
Contributions
Yong Xie designed the concept. Youhua Wang and Rulin Zhao acquired the data. Youhua Wang and Rulin Zhao performed the analysis and interpretation of the data. You-hua Wang drafted the manuscript. Ben Wang, Qiaoyun Zhao, Zhen Li, Liya Zhu-ge, and Wenzhu Yin provided a critical revision of the manuscript for important intellectual content. Youhua Wang and Ben Wang performed the statistical analysis, and Yong Xie provided study supervision.
Corresponding author
Ethics declarations
Conflict of interest
All authors approved the final version of the manuscript and declare no conflict of interest. This study was not funded by the pharmaceutical industry.
Rights and permissions
About this article
Cite this article
Wang, Y., Zhao, R., Wang, B. et al. Sequential versus concomitant therapy for treatment of Helicobacter pylori infection: an updated systematic review and meta-analysis. Eur J Clin Pharmacol 74, 1–13 (2018). https://doi.org/10.1007/s00228-017-2347-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-017-2347-7